Table 3B.
Adverse events during induction with ofatumumab and ibrutinib reported in ≥5% of patients: data are number of patients (%).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.